Compare · ABT vs CYRX
ABT vs CYRX
Side-by-side comparison of Abbott Laboratories (ABT) and CryoPort Inc. (CYRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and CYRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $157.84B, about 212.9x CYRX ($741.4M).
- Over the past year, ABT is down 31.5% and CYRX is up 118.1% - CYRX leads by 149.6 points.
- CYRX has been more active in the news (8 items in the past 4 weeks vs 7 for ABT).
- Both have 25 recent analyst ratings on file.
- Company
- Abbott Laboratories
- CryoPort Inc.
- Price
- $90.63+2.20%
- $14.72-0.44%
- Market cap
- $157.84B
- $741.4M
- 1M return
- +7.31%
- +11.98%
- 1Y return
- -31.50%
- +118.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 7
- 8
- Recent ratings
- 25
- 25
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
CryoPort Inc.
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities are maintained throughout the shipping cycle; and Cryoport Express Advanced Therapy Shippers that provides verification processes to biopharma companies. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.
Latest ABT
- Abbott declares 410th consecutive quarterly dividend
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
Latest CYRX
- Chief Digital and Tech Officer Zecchini Edward J exercised 35,000 shares at a strike of $4.80 and sold $507,563 worth of shares (35,000 units at $14.50) (SEC Form 4)
- CryoPort Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Baddour Linda was granted 10,350 shares, increasing direct ownership by 18% to 68,099 units (SEC Form 4)
- Chief Financial Officer Stefanovich Robert sold $2,756,984 worth of shares (169,427 units at $16.27), decreasing direct ownership by 61% to 109,850 units (SEC Form 4)
- Director Hancock Daniel M was granted 10,350 shares, increasing direct ownership by 18% to 69,052 units (SEC Form 4)
- Director Hariri Robert J was granted 10,350 shares, increasing direct ownership by 20% to 61,625 units (SEC Form 4)
- Director Mandalam Ramkumar was granted 10,350 shares and sold $358,452 worth of shares (23,214 units at $15.44), decreasing direct ownership by 16% to 67,894 units (SEC Form 4)
- SEC Form SD filed by CryoPort Inc.
- SEC Form 10-Q filed by CryoPort Inc.
- CryoPort Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits